Maryse Baia

Lack of reproducibility of histopathological features in MYC‐rearranged large B cell lymphoma using digital whole slide images: a study from the Lunenburg lymphoma biomarker consortium

Yasodha Natkunam, Daphne de Jong, Pedro Farinha, Philippe Gaulard et autres

AIMS: Subclassification of large B cell lymphoma (LBCL) is challenging due to the overlap in histopathological, immunophenotypical and genetic data. In particular, the criteria to separate diffuse large B cell lymphoma (DLBCL) and high-grade B cell lymphoma (HGBL) are difficult to apply …

us, nl, ca, fr, de, se, gb (code pays fourni par la source)

Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium

Andreas Rosenwald, Susanne Bens, Ranjana H. Advani, Sharon Barrans et autres

PURPOSE MYC rearrangement ( MYC-R) occurs in approximately 10% of diffuse large B-cell lymphomas (DLBCLs) and has been associated with poor prognosis in many studies. The impact of MYC-R on prognosis may be influenced by the MYC partner gene (immunoglobulin [IG] or …

de, tw, us, gb, fr, se, nl, ch, be (code pays fourni par la source)

Primary Cutaneous Follicle Center Lymphomas Expressing BCL2 Protein Frequently Harbor BCL2 Gene Break and May Present 1p36 Deletion

Vanessa Szablewski, S. Oro, Maryse Baia, Marie‐Hélène Delfau‐Larue et autres

The classification of cutaneous follicular lymphoma (CFL) into primary cutaneous follicle center lymphoma (PCFCL) or secondary cutaneous follicular lymphoma (SCFL) is challenging. SCFL is suspected when tumor cells express BCL2 protein, reflecting a BCL2 translocation. However, BCL2 expression is difficult to assess …

fr, us (code pays fourni par la source)

MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study

Christiane Copie‐Bergman, Peggy Cuillière-Dartigues, Maryse Baia, Josette Brière et autres

Diffuse large B-cell lymphoma (DLBCL) with MYC rearrangement (MYC-R) carries an unfavorable outcome. We explored the prognostic value of the MYC translocation partner gene in a series of MYC-R de novo DLBCL patients enrolled in first-line prospective clinical trials (Groupe d'Etudes des …

fr, ca, ch, de (code pays fourni par la source)

Abstract 1911: High MET and CA9 expressions define a subgroup of hepatocellular carcinoma (HCC) patients with poor prognosis candidates for MET inhibition strategy

Annemilaï Tijeras‐Raballand, Cindy Neuzillet, Miguel Albuquerque, Nathalie Colnot et autres

Abstract Background: In HCC, hypoxia and MET can promote tumor progression and induce resistance to radiation, chemo or targeted therapies. The aim of this study was to correlate MET and hypoxia marker carbonic anhydrase 9 (CA9) expression levels by immunohistochemistry with clinicopathological …

fr, de, us, ch (code pays fourni par la source)

Rituximab, alkylating agents or combination therapy for gastric mucosa‐associated lymphoid tissue lymphoma: a monocentric non‐randomised observational study

Aurélien Amiot, Michaël Lévy, Christiane Copie‐Bergman, Jehan Dupuis et autres

BACKGROUND: There is no consensus on the standard treatment of gastric mucosa-associated lymphoid tissue (MALT) lymphoma for Helicobacter pylori-negative patients and for patients with persistent disease despite H. pylori eradication. AIM: To evaluate the comparative efficacy and safety of alkylating agents and …

fr (code pays fourni par la source)

Abstract A238: c-MET as a target for MET inhibitors in patients with poor prognostic pancreatic adenocarcinoma following completed surgical resection.

Cindy Neuzillet, Jérôme Cros, Annemilaï Tijeras‐Raballand, Julien Moroch et autres

Abstract Context: Pancreatic adenocarcinoma (PAC) displays a prominent desmoplastic stromal reaction, leading to tumor hypoxia and driving a selective pressure that selects cells exhibiting aggressive phenotypes. Activation of the HGF/c-MET pathway is involved in tumor-stroma interactions and promotes PAC cells proliferation, invasion, …

fr (code pays fourni par la source)

BCL2 protein expression combined with early FDG-PET response allows improved stratification of DLBCL patients.

Christiane Copie‐Bergman, Emmanuel Itti, Julien Moroch, Violaine Safar et autres

International audience

fr, ch (code pays fourni par la source)

Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations

Meriem Chraybi, Issam Abd Alsamad, Christiane Copie‐Bergman, Maryse Baia et autres

fr (code pays fourni par la source)

Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups

Teresa Marafioti, Christiane Copie‐Bergman, Maria Calaminici, Jennifer C. Paterson et autres

AIMS: The aim of this study was to analyse the immunophenotypic and molecular features of a large series of follicular lymphomas, focusing in particular on atypical cases that fail to express CD10 and/or bcl-2. Such cases present diagnostic pitfalls, especially with regard …

gb, fr, it, my, us (code pays fourni par la source)

MYC Gene Simple Hit Is a Strong Independent Predictive Factor of Survival in Diffuse Large B-Cell Lymphomas in Contrast to MYC Double-Hit Gene Alterations: A Study by the Groupe d'Etude Des Lymphomes De l'Adulte

Christiane Copie‐Bergman, Peggy Cuillière-Dartigues, Maryse Baia, Josette Brière et autres

Abstract Abstract 541 Introduction Diffuse large B-cell lymphomas (DLBCL) represent a heterogeneous group of tumors with variable clinical, morphological, and molecular features. The International Prognostic index (IPI) imperfectly stratifies patients and does not reflect the molecular heterogeneity of the disease. New tools …

fr, ch (code pays fourni par la source)

BCL2 Negative Follicular Lymphoma with BCL6 Gene Rearrangement Show Mutations of STAT6 DNA Binding Domain

Marlène Ochmann, Christiane Copie‐Bergman, Maryse Baia, Philippe Ruminy et autres

Abstract Abstract 1559 Follicular lymphoma (FL) is the most common indolent subtype of non-Hodgkin's lymphoma in the western world. The genetic hallmark of FL is the t(14;18)(q32;q21) translocation leading to the deregulation of BCL2 expression which occurs in up to 90% of …

fr (code pays fourni par la source)